Clinical trial · Observational
Impact of Hospital Pharmacist on Drug Management in Patients With Bronchopulmonary Cancer
Impact of Hospital Pharmacist on Drug Management in Patients With Bronchopulmonary Cancer Treated by Chemotherapy and/or Immunotherapy or Oral Targeted Therapy
NCT06469957CI-TRIAL-00106068IMPACTOcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a prospective, non-interventional study to evaluate impact of hospital pharmacist on drug management in patients (only questionnaires) with bronchopulmonary cancer treated by Chemotherapy and/or Immunotherapy or Oral targeted therapy. The primary objective of the study is to evaluate the number of unscheduled consultations/hospitalizations during 6 months.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Patients With Bronchopulmonary Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Questionnaires and data collection sheet | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Impact of hospital pharmacist (interview) on the number of unscheduled consultations/hospitalizations.
- timeFrame
- From enrolment to the end of the follow up phase (6 months)
- description
- Number of unscheduled consultations or hospitalizations during the follow up phase
Secondary outcomes (6)
- measure
- Impact of hospital pharmacist (interview) on cancelled consultations/hospitalizations rate
- timeFrame
- From enrolment to the end of the follow up phase (6 months)
- description
- Number of cancelled consultations/hospitalizations
- measure
- Impact of hospital pharmacist (interview) on treatment observance (number of dispensation)
- timeFrame
- From enrolment to the end of the follow up phase (6 months)
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Male or female ≥ 18 years 2. Patient without cognitive impairments 3. Patient with bronchopulmonary cancer 4. Patient treated by chemotherapy, immunotherapy or oral targeted therapy Exclusion Criteria: 1. Patient informed and opposed to participate 2. Language barrier and lack of translator 3. Patient under guardianship, curatorship or deprived of liberty 4. Pregnant or breastfeeding women 5. Participation in any drug clinical drug trials 6. Patient with no insurance
References
Publications (1)
- BACKGROUNDBabin M, Folliard C, Robert J, Sorrieul J, Kieffer H, Augereau P, Devys C. [Pharmaceutical consultations in oncology: Implementation, one-year review and outlooks]. Ann Pharm Fr. 2019 Sep;77(5):426-434. doi: 10.1016/j.pharma.2019.05.001. Epub 2019 Jul 7. French. PMID 31288930